The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related condition, too.

Original title: “Ethyreal starts up with $101M and takes aim at a pair of immune diseases”

Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees and Cartesian boosted its ‘in vivo’ cell therapy capabilities.

Original title: “AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine”

The FDA rejected bitopertin in February amid reports of skepticism from former CBER director Vinay Prasad, who has since departed the agency.

Original title: “Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug”

The star of the licensing agreement, a small-molecule gamma-secretase modulator, will help buff Eli Lilly’s position in Alzheimer’s disease, currently headlined by its anti-amyloid antibody Kisunla.

Original title: “Lilly bets up to $1B+ with AlzeCure in search for next Alzheimer’s act”

Improved survival on display at the American Society of Clinical Oncology (ASCO) in Chicago; Pfizer’s unusual pact with China’s Innovent highlights a new type of collaboration; Eli Lilly continues its nonstop deal streak, including with Chinese biotechs; and looking ahead to this weekend’s American Diabetes Association meeting.

Original title: “ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck”

As the industry faces policy changes and significant cuts to federal funding, local ecosystems can bolster companies through innovative resources to sustain growth and keep the U.S. at the center of biomedical innovation.

Original title: “Local trade groups must support life sciences in these difficult times”

Over the past decade, Eli Lilly has bought out more biotechs than any of the other top 12 pharmas by revenue—with 10 of those acquisitions arriving just this year.

Original title: “Lilly’s $25B+ M&A spree captures half of pharma’s 2026 capacity”

Members of the American Biotech Innovation Alliance (ABIA) want to build a national biotech strategy—just like China did years ago.

Original title: “New biotech group rises to fuel American rockets in China ‘space race’”

The money will enable the addition of aseptic filling and oral solid dose capabilities to support Hikma’s products and contract manufacturing clients.

Original title: “Hikma outlines plan to invest $267M in Ohio plants, creating 350 jobs”